Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:16 AM
Ignite Modification Date:
2025-12-25 @ 1:16 AM
NCT ID:
NCT02080793
Brief Summary:
This study will be based on two questionnaires
1. One specific questionnaire that has already been developed from social sciences interviews conducted in men who have been treated for localized prostrate cancer, with a good or intermediate prognosis. This questionnaire comprises 11 pairs of scenarios. Each scenario gathers in a random manner, the modalities of 7 possible characteristics of the management strategy for localized prostrate cancer, with a good or intermediate prognosis:
* the risk of death at 5 years (modalities: 5%, 15%),
* the risk of impotence (modalities: 0%, 25%, 50%, 75%),
* the presence of urinary leaks (modalities: no protection during the day, one protection pad per day, several protection pads per day),
* the duration and frequency of care provided (modalities: 2 days of care in your whole life, 7 days of care in your whole life, 5 half-days of care per week for 8 weeks, every 3 months for 2 years then every 6 months for life),
* ablation of the prostate (modalities: Yes, No),
* the existence of possible treatments in case of aggravation or recurrence (modalities: Yes, No),
* the nature of the technology used (modalities: innovative technology, standard technology).
The objective is to ask each participant of the study for each pair of scenarios, to choose from the two scenarios (binary-choice survey), the scenario he prefers.
2. The "Spielberger Inventory Trait" scale to evaluate stable characteristics in the propensity to anxiety in study participants.
Study:
NCT02080793
Study Brief:
Protocol Section:
NCT02080793